Executive Vice President Donghyun Kim of RudaCure presentó the eficacia of the drug RCI001 currently under desarrollo at the European Ojo Seco Society anual conferencia celebrado en Krakow, Poland, which aims to address the unmet needs of enfermedad de ojo seco pacientes in Europe. Este año's event se celebró from June 19th to 21st.
The conferencia is held anually and served as an opportunity to demonstrate the excellence of RCI001 to many European ojo seco investigadores.
Additionally, during the 2025 BIO-USA period, RudaCure shared the RCI001 desarrollo progreso with Thea of France and Santen of Japan, and discutió future desarrollo issues.